notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title 新型コロナウイルス感染症の基礎知識
Subtitle 特集 ウィズコロナ時代の総合健診
Authors 忽那賢志1)
Authors (kana)
Organization 1)国立国際医療研究センター 国際感染症センター
Journal 総合健診
Volume 48
Number 2
Page 220-228
Year/Month 2021 / 3
Article 報告
Publisher 日本総合健診医学会
Abstract 「病原体」これまでにヒトに感染するコロナウイルスは4種類知られており, かぜの原因の10〜15%を占める原因ウイルスである. ヒトコロナウイルスによる急性上気道炎は夏, 秋に少なく冬や春に増えるとされており, 大規模な流行は2〜3年周期に起こるという. ヒトコロナウイルスにヒトが再感染することはしばしばあり, これは抗体の減少が比較的早く起こるためと考えられている. 2019年12月から中国の湖北省武漢市で発生した原因不明の肺炎は, 新型コロナウイルス(SARS-CoV-2)が原因であることが判明した. コロナウイルスの中ではSARS-CoVと同じベータコロナウイルスという亜属に分類される. 受容体結合遺伝子領域の構造は, SARS-CoVの構造と非常によく似ており, 細胞侵入に同じACE-2受容体を使用することが示唆されている. 「臨床症状」新型コロナウイルス感染症の潜伏期は14日以内であり, 多くの症例が曝露から概ね5日で発症する.
Practice 公衆衛生学
Keywords
  • 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
download全文ダウンロード(1.52MB)

参考文献

  • 1) Isaacs D, Flowers D, Clarke JR, Valman HB, MacNaughton MR: Epidemiology of coronavirus respiratory infections. Arch Dis Child 1983; 58(7): 500-3.
    pubmed
  • 2) Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE: Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. Journal Clin Microbiol 2010; 48(8): 2940-7.
    pubmed
  • 3) Monto AS: Medical reviews. Coronaviruses. Yale J Biol Med 1974; 47(4): 234-51.
    pubmed
  • 4) Callow KA, Parry HF, Sergeant M, Tyrrell DA: The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect 1990; 105(2): 435-46.
    pubmed
  • 5) Zhu N, Zhang D, Wang W, et al: A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
残りの47件を表示する
  • 6) Li Q, Guan X, Wu P, et al: Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382(13): 1199-207.
    pubmed
  • 7) Guan WJ, Ni ZY, Hu Y, et al: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
  • 8) Stokes EK, Zambrano LD, Anderson KN, et al: Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morbidity and Mortality Weekly Report 2020; 69(24): 759-65.
    pubmed
  • 9) Cheung KS, Hung IFN, Chan PPY, et al: Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology 2020; 159(1): 81-95.
    pubmed
  • 10) Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T: The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2020; 163(1): 3-11.
    pubmed
  • 11) Cevik M, Kuppalli K, Kindrachuk J, Peiris M: Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 2020; 371: m3862.
    pubmed
  • 12) Huang C, Wang Y, Li X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020; 395(10223): 497-506.
  • 13) Matsunaga N, Hayakawa K, Terada M, et al: Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2020. doi:10.1093/cid/ciaa1470. Epub 2020 Sep 28.
  • 14) Liang W, Guan W, Chen R, et al: Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 2020; 21(3): 335-7.
    pubmed
  • 15) Lippi G, Henry BM: Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med 2020; 167: 105941.
    pubmed
  • 16) Myers LC, Parodi SM, Escobar GJ, Liu VX: Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA 2020; 323(21): 2195-8.
  • 17) Fadini GP, Morieri ML, Longato E, Avogaro A: Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020; 43(6): 867-9.
    pubmed
  • 18) Zheng Z, Peng F, Xu B, et al: Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020; 81(2): e16-e25.
  • 19) Yang J, Zheng Y, Gou X, et al: Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Inter J Infect Dis: IJID: official publication of the International Society for Infectious Diseases 2020; 94: 91-5.
  • 20) Popkin BM, Du S, Green WD, et al: Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev 2020; 21(11): e13128.
    pubmed
  • 21) Latif F, Farr MA, Clerkin KJ, et al: Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiol 2020.
    pubmed
  • 22) Mahdavinia M, Foster KJ, Jauregui E, et al: Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract 2020; 8(7): 2388-91.
    pubmed
  • 23) Brenner EJ, Ungaro RC, Gearry RB, et al: Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020; 159(2): 481-91.e3.
  • 24) Michelena X, Borrell H, Lopez-Corbeto M, et al: Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2020; 50(4): 564-70.
  • 25) Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR: Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. Aids 2020; 34(13): F3-f8.
  • 26) Ellington S, Strid P, Tong VT, et al: Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. MMWR Morbidity and Mortality Weekly Report 2020; 69(25): 769-75.
    pubmed
  • 27) Allotey J, Stallings E, Bonet M, et al: Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370: m3320.
    pubmed
  • 28) 運営事務局・運営委員会: C-レ. COVID-19 レジストリデータを用いた新型コロナウイルス感染症における年齢別症例致命割合について.
  • 29) Carfi A, Bernabei R, Landi F: Persistent Symptoms in Patients After Acute COVID-19. JAMJ 2020; 324(6): 603-5.
  • 30) Garrigues E, Janvier P, Kherabi Y, et al: Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020.
    pubmed
  • 31) Miyazato Y, Morioka S, Tsuzuki S, et al: Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infectious Diseases 2020; 7(11): ofaa507.
    pubmed
  • 32) Shi H, Han X, Jiang N, et al: Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infectious diseases 2020.
  • 33) Wang W, Xu Y, Gao R, et al: Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; 323(18): 1843-4.
    pubmed
  • 34) Williams E, Bond K, Zhang B, Putland M, Williamson DA: Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2. J. Clin Microbiol 2020; 58(8).
    pubmed
  • 35) Wyllie AL, Fournier J, Casanovas-Massana A, et al: Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. N Engl J Med 2020; 383(13): 1283-6.
  • 36) World Health Organization: Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19): interim guidance, 12 February 2020. (オンライン)入手先
  • 37) Ogawa T, Fukumori T, Nishihara Y, et al: Another false-positive problem for a SARS-CoV-2 antigen test in Japan. J Clin Virol 2020; 131: 104612.
    pubmed
  • 38) Gandhi RT, Lynch JB, Del Rio C: Mild or Moderate Covid-19. N Engl J Med 2020; 383(18): 1757-66.
    pubmed
  • 39) Wang M, Cao R, Zhang L, et al: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
    pubmed
  • 40) Wang Y, Zhang D, Du G, et al: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England) 2020; 395(10236): 1569-78.
  • 41) Beigel JH, Tomashek KM, Dodd LE, et al: Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med 2020.
    pubmed
  • 42) Goldman JD, Lye DC, Hui DS, et al: Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020.
  • 43) Spinner CD, Gottlieb RL, Criner GJ, et al: Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020.
    pubmed
  • 44) Repurposed Antiviral Drugs for Covid-19 -- Interim WHO Solidarity Trial Results. N Engl J Med 2020.
    pubmed
  • 45) Grein J, Ohmagari N, Shin D, et al: Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; 382: 2327-36.
    pubmed
  • 46) Horby P, Lim WS, Emberson JR, et al: Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020. doi:10.1056/NEJMoa 2021436, Epub 2020 Jul 17.
  • 47) Wang D, Hu B, Hu C, et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
    pubmed
  • 48) Cheng PK, Wong DA, Tong LK, et al: Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet (London, England) 2004; 363(9422): 1699-700.
  • 49) Oboho IK, Tomczyk SM, Al-Asmari AM, et al: 2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. N Engl J Med 2015; 372(9): 846-54.
    pubmed
  • 50) Klompas M, Morris CA, Shenoy ES: Universal Masking in the Covid-19 Era. N Engl J Med 2020; 383(2): e9.
  • 51) Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL: Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA 2020; 324(7): 703-4.
  • 52) Brooks JT, Butler JC, Redfield RR: Universal Masking to Prevent SARS-CoV-2 Transmission--The Time Is Now. JAMA 2020; 324(7): 635-7.
    pubmed
はじめての方へ
個人／法人会員登録のご案内